Study Evaluating Sirolimus in the Treatment of Kidney Transplant

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The aim of this study is to test whether withdrawal of calcineurin inhibitors, followed by treatment with sirolimus, may improve renal function in renal transplant recipients with chronic allograft nephropathy.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer
• Treatments: Everolimus; Sirolimus

Criteria

Inclusion Criteria:

• Renal transplantation

• Biopsy-confirmed chronic rejection

• Treatment with mofetil mycophenolate among cyclosporine or tacrolimus

Exclusion Criteria:

• Transplant of any organ other than the kidney

• Current important infection

• Acute rejection within 12 weeks prior to inclusion